Delving into the Latest Updates on Taurocholic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

sodium taurocholate, taurocholate

Target

TGR5

Action

agonists

Mechanism

TGR5 agonists(G-protein coupled bile acid receptor 1 agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2Obesity

Originator Organization

Satiogen Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Satiogen Pharmaceuticals, Inc.

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC26H45NO7S

InChIKeyWBWWGRHZICKQGZ-HZAMXZRMSA-N

CAS Registry81-24-3

To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipeptidyl peptidase-4) inhibitors (e.g. sitagliptin) alone or in combination with metformin.

Start Date15 Sep 2016

Sponsor / Collaborator

Mayo Clinic

[+1]

ACTRN12612001213831

/ CompletedPhase 1IIT

A randomised placebo controlled crossover trial to evaluate the effects of intrajejunal taurocholic acid on gastrointestinal hormone secretion and glycaemia in response to intrajejunal glucose infusion in healthy humans for the future design of treatments for type 2 diabetes mellitus

Start Date06 Feb 2012

Sponsor / Collaborator

Royal Adelaide Hospital

ACTRN12611000071921

/ CompletedPhase 1IIT

A randomised placebo controlled crossover trial to evaluate the effects of different doses of taurocholic acid in an enema formulation on gastrointestinal hormone secretion and appetite in healthy humans for the future design of treatments for Type 2 diabetes mellitus and obesity

Start Date02 Mar 2011

Sponsor / Collaborator

Royal Adelaide Hospital

100 Clinical Results associated with Taurocholic acid

Login to view more data

100 Translational Medicine associated with Taurocholic acid

Login to view more data

100 Patents (Medical) associated with Taurocholic acid

Login to view more data

6,944

Literatures (Medical) associated with Taurocholic acid

01 Dec 2025·ENVIRONMENTAL POLLUTION

Per- and polyfluoroalkyl substances (PFAS) disrupt gut microbiome composition and metabolism in metabolic syndrome: Evidence from a host-free in vitro colonic model

Article

Author: Zhang, Huan ; Shi, Haifei ; Gao, Shuaixin ; Zhang, Shiqi ; Zhu, Jiangjiang ; Xu, Mengyang ; Chen, Li ; Guo, Chao

01 Oct 2025·Liver International

RETRACTION : Cytoprotective Effects of Taurocholic Acid Feeding on the Biliary Tree after Adrenergic Denervation of the Liver

Article

01 Oct 2025·FOOD CHEMISTRY

Synthesis, characterization, and in vitro hypolipidemic mechanisms of sugar-SA triazole conjugates as potent pancreatic lipase inhibitors

Article

Author: Ding, Han ; Sun, Yue ; Cao, Ruge ; Li, Jingxin ; Li, Yichen ; Liu, Xue-Wei ; Zhang, Xiao-Lin

100 Deals associated with Taurocholic acid

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	United States	Satiogen Pharmaceuticals, Inc.	15 Sep 2016
Obesity	Phase 2	United States	Satiogen Pharmaceuticals, Inc.	15 Sep 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02871882 (CTgov)	Phase 2	Diabetes Mellitus, Type 2 \| Obesity	24	Mixed Oral Glucose Tolerance test+Conjugated bile acids sodium (Ox Bile Extract)	vaxaqhrvjw(xmzrzzusne) = rcniiiiflw kkorbknxfh (kfqoadioln, ygmpqbwlcg - sntkdwefql) View more	-	31 May 2023
				Mixed Oral Glucose Tolerance test (Placebo)	vaxaqhrvjw(xmzrzzusne) = arotpiogzb kkorbknxfh (kfqoadioln, dwieogvkcp - tttifchhgj) View more